Fort Washington Investment Advisors Inc. OH Has $169.53 Million Stock Holdings in Becton, Dickinson and Company $BDX

Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 905,757 shares of the medical instruments supplier’s stock after acquiring an additional 17,844 shares during the period. Becton, Dickinson and Company comprises about 0.9% of Fort Washington Investment Advisors Inc. OH’s investment portfolio, making the stock its 23rd biggest position. Fort Washington Investment Advisors Inc. OH owned 0.32% of Becton, Dickinson and Company worth $169,531,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $26,000. Bell Investment Advisors Inc boosted its stake in Becton, Dickinson and Company by 474.1% in the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares in the last quarter. Bank of Jackson Hole Trust grew its position in Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares during the period. WPG Advisers LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth $36,000. Finally, CVA Family Office LLC lifted its holdings in shares of Becton, Dickinson and Company by 79.5% during the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 97 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX opened at $195.02 on Tuesday. The stock has a market cap of $55.56 billion, a P/E ratio of 33.45, a P/E/G ratio of 1.81 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The company has a fifty day simple moving average of $190.44 and a 200 day simple moving average of $186.52.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The firm had revenue of $5.32 billion for the quarter. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be issued a dividend of $1.05 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date is Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Wall Street Analyst Weigh In

BDX has been the topic of several analyst reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler reduced their price target on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Jefferies Financial Group boosted their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Finally, Stifel Nicolaus dropped their price target on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $205.64.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 629 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total transaction of $123,302.87. Following the sale, the executive vice president directly owned 13,105 shares in the company, valued at $2,568,973.15. This trade represents a 4.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,052 shares of company stock worth $201,235 over the last 90 days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.